| dc.contributor.author | RECOVERY Collaborative Group | |
| dc.date.accessioned | 2022-10-12T11:53:00Z | |
| dc.date.available | 2022-10-12T11:53:00Z | |
| dc.date.issued | 2022-01-08 | |
| dc.identifier.citation | RECOVERY Collaborative Group 2022 , ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ' , The Lancet , vol. 399 , no. 10320 , pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 | en |
| dc.identifier.issn | 0140-6736 | |
| dc.identifier.other | PURE: 209050270 | |
| dc.identifier.other | PURE UUID: fec4db84-58be-4a7f-9cb4-a39823082044 | |
| dc.identifier.other | PubMed: 34800427 | |
| dc.identifier.other | PubMedCentral: PMC8598213 | |
| dc.identifier.other | Scopus: 85122294690 | |
| dc.identifier.other | ORCID: /0000-0002-1397-4272/work/120621842 | |
| dc.identifier.uri | https://hdl.handle.net/2164/19333 | |
| dc.description | Funding UK Research and Innovation (Medical Research Council), National Institute of Health Research, and the Wellcome Trust through the COVID-19 Therapeutics Accelerator. Acknowledgments Above all, we would like to thank the thousands of patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at the participating hospitals in Nepal and Indonesia and at 176 UK National Health Service hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health and Social Care, the Intensive Care National Audit and Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage at the University of Swansea, and the NHS in England, Scotland, Wales, and Northern Ireland. The RECOVERY trial is supported by grants to the University of Oxford from the UK Research and Innovation (UKRI) and the NIHR (grant reference MC_PC_19056), the Department of Health and Social Care (DHSC), UKRI, and NIHR COVID-19 Rapid Response Grant (COV19-RECPLA), and the Wellcome Trust (grant referebce 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator. Core funding is provided by the NIHR Oxford Biomedical Research Centre, Wellcome, the Bill & Melinda Gates Foundation, the Foreign, Commonwealth, and Development Department, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from the UK Medical Research Council (MC_UU_00002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Combiphar supplied colchicine free of charge for use in this trial in Indonesia. AbbVie contributed some supplies of lopinavir-ritonavir for use in this trial. Tocilizumab was provided free of charge for this trial by Roche Products. Casivirimab and imdevimab was provided free of charge for this trial by Regeneron. The views expressed in this publication are our own and not necessarily those of the NHS or the NIHR. | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | The Lancet | en |
| dc.rights | © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/ | en |
| dc.subject | R Medicine | en |
| dc.subject | National Institute for Health Research (NIHR) | en |
| dc.subject | MC_PC_19056 | en |
| dc.subject | COV19-RECPLA | en |
| dc.subject | NIHR-SRF-2015-08-001 | en |
| dc.subject | Wellcome Trust | en |
| dc.subject | 222406/Z/20/Z | en |
| dc.subject | Medical Research Council (MRC) | en |
| dc.subject | MC_UU_00002/14 | en |
| dc.subject | Supplementary Data | en |
| dc.subject.lcc | R | en |
| dc.title | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial | en |
| dc.type | Journal article | en |
| dc.contributor.institution | University of Aberdeen.Health Services Research Unit | en |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.description.status | Peer reviewed | en |
| dc.description.version | Publisher PDF | en |
| dc.identifier.doi | https://doi.org/10.1016/S0140-6736(21)01825-0 | |
| dc.identifier.vol | 399 | en |
| dc.identifier.iss | 10320 | en |
